BioPharma Dive: A 21st century diabetes option: Will Oramed be first to market with oral insulin?

Josh Hexter, Oramed’s COO, spoke with BioPharma Dive about Oramed’s product and progress.
“Our oral insulin is not a substitute for insulin injections, but rather a new, earlier treatment option.”

You may also be interested

Join our mailing list

Skip to content